• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer
  • Advertise
  • Subscribe

MassDevice

The Medical Device Business Journal — Medical Device News & Articles | MassDevice

  • Latest News
  • Technologies
    • Artificial Intelligence (AI)
    • Cardiovascular
    • Orthopedics
    • Neurological
    • Diabetes
    • Surgical Robotics
  • Business & Finance
    • Wall Street Beat
    • Earnings Reports
    • Funding Roundup
    • Mergers & Acquisitions
    • Initial Public Offering (IPO)
    • Legal News
    • Personnel Moves
    • Medtech 100 Stock Index
  • Regulatory & Compliance
    • Food & Drug Administration (FDA)
    • Recalls
    • 510(k)
    • Pre-Market Approval (PMA)
    • MDSAP
    • Clinical Trials
  • Special Content
    • Special Reports
    • In-Depth Coverage
    • DeviceTalks
  • Podcasts
    • MassDevice Fast Five
    • DeviceTalks Weekly
    • OEM Talks
      • AbbottTalks
      • Boston ScientificTalks
      • DeviceTalks AI
      • IntuitiveTalks
      • MedtechWOMEN Talks
      • MedtronicTalks
      • Neuro Innovation Talks
      • Ortho Innovation Talks
      • Structural Heart Talks
      • StrykerTalks
  • Resources
    • About MassDevice
    • DeviceTalks
    • Newsletter Signup
    • Leadership in Medtech
    • Manufacturers & Suppliers Search
    • MedTech100 Index
    • Videos
    • Webinars
    • Whitepapers
    • Voices
Home » Abbott’s rapid COVID-19 self-test is now over-the-counter

Abbott’s rapid COVID-19 self-test is now over-the-counter

April 1, 2021 By Sean Whooley

BinaxNow COVID-19 Ag Card
The BinaxNow COVID-19 Ag Card [Image courtesy of Abbott]
Abbott (NYSE:ABT) announced that it received FDA emergency use authorization (EUA) for over-the-counter use of its BinaxNOW COVID-19 test.

The new indication for the diagnostic allows individuals with or without symptoms to access the BinaxNOW COVID-19 Ag self-test over the counter, without a prescription. The company plans to begin shipping to major food, drug and mass merchandiser retailers in the coming weeks. It also anticipates availability through some online stores, according to a news release.

Abbott Park, Ill.-based Abbott said it expects the BinaxNOW self test to be priced affordably – similar to common OTC tests, of which a couple of others were authorized by the FDA, today, too.

The Quidel Quick-View at-home test and the BD Veritor Plus system, which was authorized for POC screening with a prescription, joining Abbott’s BinaxNOW test as authorized OTC COVID-19 diagnostics. The FDA said the addition of the OTC and POC tests for screening will offer schools, workplaces, communities and others several options for serial screening tests that are both accurate and reliable.

The BinaxNOW test can be used on children as young as 2 when samples are collected by an adult plus all people aged 15 years or older. The rapid antigen test will come in a two-count box.

Those using the test will only need to perform a minimally invasive nasal swab, rather than a deep nasopharyngeal swab, with all materials required to perform the test to be provided in the two-count box.

BinaxNow was initially authorized and launched in August, while Abbott has since scaled up production at new U.S. manufacturing facilities to produce 50 million tests per month. Almost straight away, the U.S. government purchased 150 million tests for $750 million. Workplaces, schools and other organizations across the U.S. have been using the tests since.

“We’ve now accomplished what we set out to do when we launched BinaxNOW, which is to bring an accurate, affordable and readily available test to the American people that they can have on hand, whether they want to test frequently or in certain circumstances,” Abbott president & CEO Robert B. Ford said in the release. “Together with vaccines, the BinaxNOW self test will help Americans get back to doing what they want and need to do – like going to work and school or seeing friends and family – with greater confidence.”

Filed Under: Business/Financial News, Diagnostics, Featured, Food & Drug Administration (FDA), Genomics/Molecular Diagnostics, Regulatory/Compliance Tagged With: Abbott, coronavirus, COVID-19, FDA

More recent news

  • SS Innovations completes first robotic telesurgery for weight loss
  • Johnson & Johnson MedTech adds new CMO for its Electrophysiology business
  • Abbott earns Medicare win for TriClip TEER system
  • Judge says Johnson & Johnson Ethicon owes $76.6M to ChemImage after failed partnership
  • Aurora Spine begins first procedures with Aero lumbar fusion system

About Sean Whooley

Sean Whooley is an associate editor who mainly produces work for MassDevice, Medical Design & Outsourcing and Drug Delivery Business News. He received a bachelor's degree in multiplatform journalism from the University of Maryland, College Park. You can connect with him on LinkedIn or email him at [email protected].

Primary Sidebar

“md
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest med device regulatory, business and technology news.

DeviceTalks Weekly

See More >

MEDTECH 100 Stock INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
MDO ad

Footer

MASSDEVICE MEDICAL NETWORK

DeviceTalks
Drug Delivery Business News
Medical Design & Outsourcing
Medical Tubing + Extrusion
Drug Discovery & Development
Pharmaceutical Processing World
MedTech 100 Index
R&D World
Medical Design Sourcing

DeviceTalks Webinars, Podcasts, & Discussions

Attend our Monthly Webinars
Listen to our Weekly Podcasts
Join our DeviceTalks Tuesdays Discussion

MASSDEVICE

Subscribe to MassDevice E-Newsletter
Advertise with us
About
Contact us

Copyright © 2025 · WTWH Media LLC and its licensors. All rights reserved.
The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media.

Privacy Policy